FMP

FMP

Enter

CRL - Charles River L...

photo-url-https://images.financialmodelingprep.com/symbol/CRL.png

Charles River Laboratories International, Inc.

CRL

NYSE

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

171.04 USD

4.11 (2.4%)

Historical Prices

From:

To:

168.82169169.5170170.5171171.509:30 AM09:52 AM10:12 AM10:32 AM10:52 AM11:12 AM11:32 AM11:52 AM12:12 PM12:32 PM12:52 PM01:12 PM01:32 PM01:52 PM02:12 PM02:32 PM02:52 PM03:12 PM03:32 PM03:52 PM

About

ceo

Mr. James C. Foster J.D.

sector

Healthcare

industry

Medical - Diagnostics & Research

exchange

NYSE

Description

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, includi...

CIK

0001100682

ISIN

US1598641074

CUSIP

159864107

Address

251 Ballardvale Street

Phone

781 222 6000

Country

US

Employee

18,700

IPO Date

Jun 23, 2000

Financial Statement

-400M-200M0200M400M600M800M1B1.2B2023 Q42024 Q12024 Q22024 Q32024 Q4RevenueNet Income

Earnings

00.511.522.532023 Q22023 Q32023 Q32023 Q42024 Q12024 Q22024 Q32024 Q4EPS Consensus

CRL Financial Summary

CIK

0001100682

Exchange

NYSE

Industry

Medical - Diagnostic...

Sector

Healthcare

CUSIP

159864107

ISIN

US1598641074

Country

US

Price

171.04

Beta

1.45

Volume Avg.

1.08M

Market Cap

8.75B

Shares

-

52-Week

150.79-274.77

DCF

121.17

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

855.2

P/B

-

Website

https://www.criver.com

Upgrades and Downgrades

Rating Distribution

Buy0

Hold1

Sell0

TheFly

11 days ago
Mar 4, 2025

Sell

Neutral

Latest CRL News

Rayan Ahmad

3 days ago

Cresco Labs Financial Performance Analysis

Cresco Labs, trading under the symbol CRLBF on the PNK exchange, is a prominent player in the cannabis industry. The company is known for its cultivation, manufacturing, and retail operations across the United States. As Cresco Labs prepares to release its quarterly earnings on March 12, 2025, investors are eager to see how the company has performed financially in the fourth quarter of 2024. Wall Street estimates that Cresco Labs will report an earnings per share (EPS) of -$0.02. This negative ...

Seeking Alpha

Aug 15, 2024

Charles River Laboratories: Changing Economics Reduces Compo...

Charles River came in with another set of soft numbers, indicating a period of weaker business ahead for the company. Management is scaling back CapEx into the business and focusing on buybacks, suggesting there's no viable reinvestment opportunities to grow. The intrinsic worth of the business is $215–$223/share under present conditions, in my opinion, warranting a hold.

Zacks Investment Research

Aug 12, 2024

Why Charles River (CRL) International Revenue Trends Deserve...

Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Seeking Alpha

Aug 10, 2024

Charles River Laboratories: Q2, Cost Structure Streamlining ...

Weak biopharma market challenges persist, impacting CRL's revenue and bottom-line growth. Cost streamlining initiatives in place to generate $150 million in annualized cost savings by FY25. Growth projection includes a 3% revenue decline in FY24, with a fair value of $220 per share based on DCF analysis.

Alex Lavoie

Aug 8, 2024

Charles River Laboratories Faces Downturn Amid Revised Sales...

Charles River Laboratories International, Inc. (NYSE:CRL) faced a significant downturn in its stock performance, with a notable 12% drop in intraday trading on a recent Wednesday. This decline was triggered by the company's announcement of an expected decrease in sales for the full fiscal year, deviating from its prior growth forecasts. Despite achieving second-quarter revenue of $1.03 billion, aligning with estimates, and surpassing profit expectations with $94.08 million, the company observed ...

Zacks Investment Research

Aug 7, 2024

Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Do...

Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.

Investopedia

Aug 7, 2024

Charles River Labs Says It Expects Sales To Fall, Sending It...

Shares of Charles River Laboratories (CRL) tumbled over 12% in intraday trading Wednesday after the company said it expects to post a decline in sales for the full fiscal year, instead of growth.

Zacks Investment Research

Aug 7, 2024

Charles River Laboratories (CRL) Surpasses Q2 Earnings and R...

Charles River Laboratories (CRL) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.39 per share. This compares to earnings of $2.69 per share a year ago.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep